InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,815.03
(
0.61%
)
US TECH 100
19,700.00
(
-0.02%
)
Dow Jones
42,863.86
(
0.97%
)
Brent Oil
78.70
(
0.00%
)
Bitcoin
62,724.52
(
0.44%
)
Post# of 253346
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 840
Posts 120561
Boards Moderated 14
Alias Born 09/05/2002

DewDiligence

Member Level

Re: NP1986 post# 123206

Monday, 07/11/2011 4:26:06 PM

Monday, July 11, 2011 4:26:06 PM

Post# of 253346

IIRC, MUC1 is poorly glycosylated in cancer cells as opposed to normal cells. As a result, MUC1 on cancer cells is supposedly more "exposed".

If proper glycosylation is what makes it work, they’d better make money quickly before the patent runs out and the product goes generic… there’s a company I know that’s pretty good at characterizing stuff like that :- )

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up